Genomic polymorphisms of drug metabolisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (GEM) or taxanes.

被引：0
|
作者：
Zhang, L. [1 ]
Zhou, C. [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7627
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Genetic polymorphisms correlate with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX)
    Yamamoto, N.
    Sato, Y.
    Tamura, T.
    Kunitoh, H.
    Ohe, Y.
    Katori, N.
    Sawada, J.
    Sekine, A.
    Nakamura, Y.
    Saijo, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine
    Xiaoxia Chen
    Ling Zhang
    Shengxiang Ren
    Xuefei Li
    Fei Zhou
    Wei Li
    Guanghui Gao
    Yayi He
    Caicun Zhou
    Medical Oncology, 2014, 31
  • [3] Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine
    Chen, Xiaoxia
    Zhang, Ling
    Ren, Shengxiang
    Li, Xuefei
    Zhou, Fei
    Li, Wei
    Gao, Guanghui
    He, Yayi
    Zhou, Caicun
    MEDICAL ONCOLOGY, 2014, 31 (04)
  • [4] EFFECT OF GEMCITABINE PATHWAY GENETIC POLYMORPHISMS ON OVERALL SURVIVAL OF NON-SMALL CELL LUNG CANCER TREATED WITH GEMCITABINE.
    Li, L.
    Schaid, D. J.
    Fridley, B. L.
    Abo, R. P.
    Kalari, K.
    Jenkins, G.
    Batzler, A.
    Pelleymounter, L. L.
    Sun, Z.
    Yang, P.
    Wang, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S67 - S68
  • [5] Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).
    Suk, R
    Park, S
    Liu, G
    Cogan-Drew, T
    Zhou, W
    Su, L
    Lynch, T
    Wain, J
    Christiani, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 842S - 842S
  • [6] Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC)
    Casal, J
    Grande, C
    Caeiro, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1083 - 1083
  • [7] Genome-wide association scan detected candidate polymorphisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX)
    Sato, Y.
    Yamamoto, N.
    Kunitoh, H.
    Ohe, Y.
    Katori, N.
    Sawada, J.
    Sakamoto, H.
    Saijo, N.
    Yoshida, T.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Gemcitabine (GEM) plus vinorelbine (NVB) in non-small cell lung cancer (NSCLC)
    Michetti, G
    Beretta, GD
    Belometti, MO
    Gritti, G
    Marini, B
    Agazzi, A
    Labianca, R
    ANNALS OF ONCOLOGY, 1998, 9 : 91 - 92
  • [9] Phase I study of gemcitabine (GEM) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC).
    Kawabata, S
    Oka, M
    Fukuda, M
    Kinoshita, A
    Fukuda, M
    Nagashima, S
    Nakamura, Y
    Nakano, H
    Soda, H
    Kohno, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 688S - 688S
  • [10] Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2233 - S2234
12345